阅读说明：本技术 用于过敏治疗的基于表位的方法和克罗恩病的抑制剂 (Epitope-based methods and inhibitors of Crohn's disease for allergy treatment ) 是由 扎卡里·阿普特 杰西卡·里克曼 丹尼尔·阿莫纳西德 马里奥·萨维德拉 英格丽德·阿拉亚 于 2020-03-13 设计创作，主要内容包括：本公开涉及用于治疗过敏和克罗恩病的药物化合物和组合物以及方法。治疗过敏的方法可以包括(a)基于微生物组和过敏原的蛋白质组预测潜在表位；(b)过滤步骤a)中获得的潜在表位以产生一系列表位；以及(c)再造步骤b)中获得的所述一系列表位以产生新的表位。治疗克罗恩病的方法可以包括(a)鉴定HLA II类蛋白和/或血细胞凝集素针对I2超抗原的一个或多个结合区；(b)确定对应于所述一个或多个结合区的第一肽序列；以及(c)产生具有作为第一肽序列的突变的第二肽序列的肽抑制剂,其中相比第一肽序列,第二肽序列与I2超抗原具有更强的结合亲和力。(The present disclosure relates to pharmaceutical compounds and compositions and methods for treating allergy and crohn's disease. Methods of treating allergy can include (a) predicting potential epitopes based on microbiome and proteome of allergens; (b) filtering the potential epitopes obtained in step a) to generate a range of epitopes; and (c) recreating the series of epitopes obtained in step b) to generate new epitopes. Methods of treating crohn's disease may include (a) identifying one or more binding regions for HLA class II proteins and/or haemagglutinin to I2 superantigens; (b) determining a first peptide sequence corresponding to the one or more binding regions; and (c) producing a peptide inhibitor having a mutated second peptide sequence as the first peptide sequence, wherein the second peptide sequence has a stronger binding affinity to the I2 superantigen than the first peptide sequence.)